Price movement over the last 24 hours
Apple Inc vs Hims and Hers Health Inc — how do they compare? Apple Inc trades at $313.23 (market cap $4.56T), while Hims and Hers Health Inc trades at $35.92 (market cap $8.37B). The key difference: Apple Inc is far larger — about 544.8× Hims and Hers Health Inc's market cap, and Apple Inc pays a 0.35% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| AAPL | HIMS | |
|---|---|---|
Market Cap | $4.56T | $8.37B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $315.20 | $66.18 |
52-Week Low | $202.38 | $14.52 |
Enterprise Value | $4.58T | $8.75B |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $313.28, up 0.2% on the day, with a bullish technical signal and strong support at $309. Recent earnings beats and a 26.91% net margin in 2025 highlight robust profitability. Revenue grew to $416.16B in 2025, with further growth projected to $451.4B in 2026. Positive news includes leading smartphone shipments and institutional buying, though union-busting allegations and potential Q2 2026 earnings miss pose concerns.
Outlook remains positive with a consensus price target of $329.62, offering ~5% upside. Strengths include high margins, cash flow generation, and AI opportunities via 2.5B device base. Risks involve competitive pressures, regulatory scrutiny from EU fines, and reliance on iPhone sales. Analyst sentiment is bullish (63% buy ratings), but investors should monitor execution against earnings expectations.
Hims & Hers Health trades at $38.28, up 4.02% today, showing strong momentum near its 52-week high. The stock exhibits a bullish technical trend with support at $37 and resistance at $39. Fundamentally, revenue reached $2.35 billion in 2025 with a gross margin of 71.72%, though net income turned negative in 2026. Recent news highlights growth in weight-loss subscriptions and a price target increase from Canaccord Genuity to $40 (July 1, 2026).
The outlook is mixed: bullish technicals and subscriber growth contrast with high valuation multiples (P/E 57.14) and recent earnings misses. Key risks include execution in competitive telehealth and reliance on obesity drug trends. Analysts are cautious with 65% hold ratings, consensus target $33.43 suggests limited upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →